Secukinumab
Brand: Cosentyx
Immunomodulator
IL-17A monoclonal antibody
Pharmacokinetics
| Half-life | 27 days |
| Clearance Route | reticuloendothelial |
| Active Metabolites | none |
| Notes | IgG1 monoclonal antibody; cleared by proteolytic pathways. Loading doses required due to long t½. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Infections (URTI common), Candida infections, neutropenia, inflammatory bowel disease flare
Contraindications:
Active infections
Precautions:
Monitor for infections; caution in Crohn’s/ulcerative colitis; avoid live vaccines